News & Updates

New drug applications approved by US FDA as of 1-15 April 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

The use of sodium-glucose cotransporter type 2 (SGLT2) inhibitors lowers the risk of incident gout or recurrent gout flares among patients with type 2 diabetes who are taking metformin, as shown in a study.

Use of glucagon-like peptide 1 (GLP1) receptor agonists does not contribute to an elevated risk of thyroid cancer, as shown in a Scandinavian cohort study with a mean follow-up of nearly 4 years.

For individuals with diabetes mellitus (DM), optimal glycaemic control may protect against the risk of developing colonic adenoma and colorectal cancer (CRC), as reported in a population-based cohort study.

Patients using multiple insulin injections demonstrate no significant difference in changes to A1c, insulin requirements, or weight after a year of treatment with a sodium glucose transporter 2 (SGLT2) inhibitor or glucagon-like peptide 1 (GLP1) receptor agonist, as shown in a study.

For patients with type 2 diabetes (T2D) and metabolic dysfunction-associated steatotic liver disease (MASLD) cirrhosis, treatment with glucagon-like peptide-1 receptor agonists helps reduce the risk of hepatic decompensation, portal hypertension, hepatocellular carcinoma, and liver transplantation, according to a study.